|Day Low/High||88.21 / 89.92|
|52 Wk Low/High||74.97 / 96.31|
As part of the agreement, Ionis and Akcea are eligible to receive $225 million in near-term payments.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
One of the announcements include the hiring of former Novartis executive Christi Shaw to lead the biomedicines business starting April 3.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
The health care sector has been a miserable performer lately -- but these five health trades are bucking the trend.
Jim Cramer says he's still 'a believer' in KKR and Opko.
Stocks kept rallying right through and after this rate hike, says Jim Cramer.
There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.
Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.
Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
Another day, another industry damaged by the president-elect's rhetoric. But these three companies are strong enough to overcome arm-twisting over drug prices.
Stocks enjoyed another strong day on Wall Street as the financial sector pushed the S&P 500 higher.
The Dow trades at an all-time high Monday as the financial and energy sectors rise.
I spent the weekend with thousands of blood disease researchers. This is what happened.
The Dow trades at an all time high Monday as crude oil climbs higher and markets shrug off potential negative effects of Italy's 'no' vote on its constitutional reform referendum.
Stock futures rise Monday as crude oil continues to climb higher and markets shrug off potential negative effects of Italy's 'no' vote on its constitutional reform referendum.
Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.
'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.
Each dividend stock scores well for safety and has a historically high dividend yield.
Wall Street scores a trifecta of record closes on Monday as a crude oil rally gives stocks an across-the-board boost.
Wall Street is on track for record closes for all the benchmark indices as crude oil resumes its rally.
Stocks are higher on Monday as an early-morning surge in crude oil prices plateaus around $47 a barrel.
U.S. stocks rose early Monday as investors parsed comments from oil officials in Iran and Iraq, hinting at a production cut at next week's OPEC meeting.
Stock futures edge higher on Monday morning as investors pin hopes on a production freeze agreement among major oil producers.
European stocks turned positive amid bullish oil sentiment ahead of November 30 OPEC meeting.
Novartis is entering into talks to purchase Amneal Pharmaceuticals in a deal that could value the company at $8 billion.
Jim Cramer says take a pass on TGT and the dollar stores; look at AMZN instead.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.